FDA hands Bristol Myers a landmark approval in early-stage lung cancer after just five days

On Feb. 28, the FDA accepted Bristol Myers Squibb’s application for approval of a new use of blockbuster checkpoint inhibitor Opdivo and said it would make a decision by July 13.

That estimate turned out to be conservative, to say the least. On Friday, just five days after accepting the application, the FDA OK’d it, handing the Big Pharma a landmark approval.